PRKCA and neoplasm: Specifically inhibits PKC‐α protein expression, blocks tumor cell proliferation, survival, and drug resistance‐related signaling pathways, and can be combined with carboplatin and paclitaxel to synergistically enhance antitumor effects through multiple targets, thereby improving chemotherapy sensitivity.